global
influenzalik
ill
ili
also
known
acut
respiratori
ill
common
caus
morbid
mortal
develop
develop
temper
climat
ili
report
throughout
year
amongst
hospit
patient
mark
increas
case
record
winter
period
also
evid
sporad
background
activ
ili
transmiss
throughout
year
amongst
commun
tropic
climat
slight
increas
case
raini
howev
littl
known
aetiolog
agent
ili
develop
countri
make
challeng
plan
implement
effect
patient
manag
diseas
prevent
control
surveil
monitor
programm
ili
scale
mani
countri
primarili
trigger
increas
threat
zoonosi
emerg
pandemicpron
respiratori
virus
need
identifi
document
incid
endem
circul
pathogen
inform
import
differenti
diagnosi
outbreak
investig
trend
analysi
earli
recognit
emerg
reemerg
virus
implement
specif
public
health
intervent
mass
vaccin
campaign
uganda
tropic
countri
lie
along
equat
surveil
influenza
start
juli
june
influenza
virus
confirm
patient
present
ili
health
facil
impli
aetiolog
remain
studi
uganda
identifi
influenza
virus
respiratori
syncyti
virus
parainfluenza
virus
coxsackievirus
echovirus
caus
agent
ili
studi
conduct
recent
result
countri
includ
seneg
cote
ivoir
kenya
madagascar
shown
virus
circul
togeth
newlydiscov
virus
coronavirus
bocavirus
current
studi
identifi
respiratori
virus
associ
ili
patient
seek
healthcar
kampala
citi
entebb
town
locat
central
region
uganda
studi
carri
nation
protocol
routin
surveil
human
influenza
uganda
patient
age
present
ili
sentinel
surveil
site
influenza
kiswa
health
centr
ugandan
capit
kampala
entebb
hospit
entebb
town
enrol
crosssect
studi
august
decemb
two
studi
site
separ
approxim
km
use
world
health
organ
modifi
criterion
use
ili
case
defin
individu
present
fever
two
follow
clinic
sign
cough
sore
throat
myalgia
headach
maximum
five
elig
case
enrol
day
studi
site
patient
demograph
characterist
clinic
histori
record
standardis
clinic
form
present
relat
symptom
short
breath
conjunct
diarrhoea
vomit
also
record
inform
obtain
caregiv
patient
unabl
speak
child
laboratori
test
carri
nation
influenza
centr
nic
locat
uganda
viru
research
institut
entebb
uganda
laboratori
nation
refer
centr
human
influenza
surveil
uganda
particip
routin
extern
qualiti
assess
panel
programm
influenza
virus
nasopharyng
swab
puritan
medic
product
compani
llc
main
usa
collect
studi
particip
specimen
collect
health
centr
place
immedi
viral
transport
media
dulbecco
modifi
eagl
highveld
biolog
ltd
lyndhurst
south
africa
supplement
serum
albumin
uml
penicillin
uml
streptomycin
store
liquid
nitrogen
transport
nic
analysi
commerciallyavail
multiplex
pcr
kit
rv
detect
seegen
inc
rockvil
md
usa
detect
adenoviru
influenza
b
virus
respiratori
syncyti
virus
b
human
metapneumoviru
parainfluenza
virus
rhinoviru
coronavirus
use
kit
use
elsewher
identifi
respiratori
virus
similar
assay
perform
accord
manufactur
instruct
briefli
total
nucleic
acid
ribonucl
acid
rna
deoxyribonucl
acid
dna
extract
collect
specimen
viral
genespintm
intron
biotechnolog
gyeonggido
korea
target
sequenc
present
extract
revers
transcrib
rna
form
amplifi
two
separ
assay
multiplex
polymeras
chain
reaction
pcr
mpcr
use
virusspecif
kit
primer
one
assay
contain
primer
adenoviru
amplicon
size
bp
human
metapneumoviru
bp
coronaviru
bp
parainfluenza
viru
bp
parainfluenza
viru
bp
parainfluenza
viru
bp
whilst
mpcr
assay
primer
set
influenza
viru
bp
influenza
b
viru
bp
respiratori
syncyti
viru
b
bp
rhinoviru
bp
respiratori
syncyti
viru
bp
coronaviru
bp
amplifi
product
observ
use
agaros
gel
electrophoresi
specimen
match
band
correspond
expect
amplicon
size
type
viru
rel
molecular
weight
marker
score
posit
viru
kit
posit
neg
control
also
includ
everi
assay
run
intern
posit
control
also
includ
evalu
amplif
effici
test
specimen
data
collect
patient
part
routin
healthcar
deliveri
anonym
uganda
ministri
health
guidelin
requir
ethic
review
inform
verbal
consent
obtain
studi
particip
caregiv
studi
conduct
follow
nation
guidelin
influenza
surveil
establish
ugandan
ministri
health
thu
studi
particip
identifi
recruit
train
healthcar
worker
use
modifi
case
definit
ili
addit
laboratori
procedur
perform
collabor
refer
laboratori
follow
kit
manufactur
instruct
specimen
collect
laboratori
test
method
use
elsewher
similar
august
decemb
total
studi
particip
present
ili
two
studi
centr
recruit
particip
entebb
hospit
particip
kiswa
health
centr
tabl
gender
repres
almost
equal
proport
femal
male
median
age
year
rang
half
studi
particip
age
year
less
low
form
educ
patient
seen
outpati
depart
two
studi
site
none
requir
hospit
admiss
time
enrol
apart
fever
common
clinic
symptom
cough
short
breath
headach
n
studi
particip
report
presenc
chronic
condit
ill
activ
tuberculosi
chronic
cough
chest
pain
almost
particip
report
clinic
within
three
day
rang
onset
symptom
swab
specimen
collect
analys
posit
one
respiratori
agent
frequentlydetect
respiratori
viru
amongst
studi
particip
influenza
n
other
adenoviru
n
rhinoviru
n
coronaviru
n
leastdetect
respiratori
virus
parainfluenza
viru
n
coronaviru
n
tabl
approxim
viral
detect
includ
parainfluenza
virus
adenoviru
coronaviru
detect
studi
particip
age
year
less
rhinoviru
influenza
virus
detect
across
age
test
posit
respiratori
agent
case
mix
infect
two
three
virus
patient
infect
three
virus
twentyon
case
infect
two
virus
frequent
mixtur
adenoviru
influenza
viru
n
frequent
viral
mixtur
adenoviru
rhinoviru
n
influenza
viru
coronaviru
n
tabl
adenoviru
present
n
mix
infect
almost
half
detect
viru
respiratori
syncyti
viru
b
aetiolog
detect
mix
infect
studi
identifi
viral
aetiolog
ili
case
two
health
facil
kampala
entebb
uganda
preval
level
similar
report
identifi
aetiolog
includ
influenza
b
viru
adenoviru
rhinoviru
coronaviru
parainfluenza
viru
respiratori
syncyti
viru
b
human
metapneumoviru
number
aetiolog
recent
identifi
circul
uganda
unknown
previous
includ
human
metapneumoviru
whose
discoveri
caus
agent
ili
recognis
last
detect
virus
includ
parainfluenza
viru
influenza
b
viru
adenoviru
human
metapneumoviru
coronavirus
circul
preval
level
gener
similar
found
influenza
viru
detect
ili
case
higher
preval
level
known
exist
previou
observ
higher
preval
observ
viru
could
attribut
time
studi
conduct
rainfal
highest
uganda
probabl
outbreak
associ
viru
ongo
studi
period
observ
convers
rhinoviru
detect
lower
preval
level
found
ili
surveil
studi
within
subsaharan
studi
preval
respiratori
syncyti
virus
b
rang
higher
total
preval
virus
low
preval
level
observ
virus
could
also
associ
season
studi
popul
variabl
could
establish
current
crosssect
data
also
ili
case
definit
focus
influenza
surveil
could
restrict
regard
sign
symptom
ili
mix
infect
amongst
case
test
posit
respiratori
agent
account
find
major
doubl
infect
preval
mix
infect
rang
report
studi
depend
geograph
locat
studi
area
diagnost
method
use
gener
degre
ill
studi
high
preval
mix
influenza
viru
adenoviru
infect
low
circul
cycl
respiratori
syncyti
viru
infect
previous
studi
number
mix
infect
n
adequ
allow
statist
analysi
comprehens
studi
necessari
order
determin
associ
interact
virus
well
relat
clinic
outcom
studi
number
limit
firstli
number
virus
detect
multiplex
pcr
kit
limit
possibl
respiratori
virus
circul
studi
popul
identifi
secondli
nasopharyng
swab
collect
possibl
miss
virus
lower
respiratori
tract
thirdli
studi
period
limit
four
month
epidemiolog
aspect
associ
virus
season
could
establish
shown
viral
aetiolog
ili
studi
popul
caus
influenza
virus
inform
vital
use
futur
guid
policymak
respiratori
diseas
surveil
case
manag
uganda
